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Axonal amyloid precursor protein and its 
fragments undergo somatodendritic endocytosis 
and processing
Emily D. Niederst*, Sol M. Reyna, and Lawrence S. B. Goldstein
Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093
ABSTRACT Deposition of potentially neurotoxic Aβ fragments derived from amyloid precur-
sor protein (APP) at synapses may be a key contributor to Alzheimer’s disease. However, the 
location(s) of proteolytic processing and subsequent secretion of APP fragments from highly 
compartmentalized, euploid neurons that express APP and processing enzymes at normal 
levels is not well understood. To probe the behavior of endogenous APP, particularly in hu-
man neurons, we developed a system using neurons differentiated from human embryonic 
stem cells, cultured in microfluidic devices, to enable direct biochemical measurements from 
axons. Using human or mouse neurons in these devices, we measured levels of Aβ, sAPPα, 
and sAPPβ secreted solely from axons. We found that a majority of the fragments secreted 
from axons were processed in the soma, and many were dependent on somatic endocytosis 
for axonal secretion. We also observed that APP and the β-site APP cleaving enzyme were, 
for the most part, not dependent on endocytosis for axonal entry. These data establish that 
axonal entry and secretion of APP and its proteolytic processing products traverse different 
pathways in the somatodendritic compartment before axonal entry.
INTRODUCTION
Alterations of expression or processing of amyloid precursor protein 
(APP) are pathogenic (Bertram et al., 2010) and may lead to the 
characteristic synapse loss and neuronal death, which are key fea-
tures of Alzheimer’s disease (AD; Coleman and Yao, 2003; Wei et al., 
2009).
Despite extensive research into the mechanisms controlling pro-
teolytic cleavage of APP, the subcellular location of processing and 
the relationship of proteolytic processing to sorting pathways in 
neurons remains unclear. Full-length APP undergoes multiple prote-
olytic processing events, typically an α- or β-site cleavage step fol-
lowed by γ-site cleavage by secretase proteins (Haass et al., 2012). 
Sorting of APP and its proteolytic fragments in bona fide neurons is 
less understood, with evidence for multiple pathways, including 
dendritic to axon sorting and axon transport preceding dendritic 
sorting (Simons et al., 1995; Yamazaki et al., 1995; Koo et al., 1996). 
In addition, APP and the secretase β-site APP-cleaving enzyme 
(BACE), which mediates amyloidogenic β-site cleavage events, are 
internalized through endocytosis via different endocytic pathways 
(Schneider et al., 2008; Sannerud et al., 2011; Morel et al., 2013). 
Importantly, and in contrast to nonpolarized cells, neurons have so-
phisticated sorting systems most similar to the pathways found in 
polarized epithelia. These pathways may also be altered substan-
tially when APP and the secretases are overexpressed during typical 
experimental protocols.
Current evidence does not distinguish among multiple models 
for the location of APP processing in neurons and the sorting of full-
length APP (FL-APP) and its fragments into axons. One model pos-
tulates that most APP is processed in the cell body and APP cleav-
age products are sorted into independent vesicles before entering 
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To better understand endogenous APP processing, localization, 
secretion, and sorting of APP and its fragments in neurons, we took 
advantage of compartmentalized culture systems that enable bio-
chemical analyses by separating axons from bulk neuronal cultures 
(Taylor et al., 2005; Park et al., 2009). To test whether the details of 
APP processing are conserved between mice and humans, we also 
developed a compartmentalized system suitable for human 
neurons.
We determined, in mouse and human neurons, that a significant 
majority of endogenous APP proteolytic fragments secreted from 
axons were processed in the neuronal soma. Additionally, we found 
that APP proteolytic fragments secreted from axons were gener-
ated in a pathway that depends upon somatic endocytosis. In con-
trast, full-length unprocessed APP and BACE appeared to be 
sorted into axons through at least two pathways, one dependent 
on endocytosis, one not. These results suggest that sorting and 
processing of APP in neurons is more complex and highly regu-
lated than previously thought and involves a minimum of two sepa-
rable pathways.
RESULTS
Human neurons differentiated from embryonic stem cells
To obtain human neurons in sufficient quantities for biochemical 
measurements, we developed a method to differentiate neurons 
from human embryonic stem cells (hESCs). This protocol produces 
postmitotic neurons expressing endogenous amounts of human 
proteins. The timeline and procedure is briefly outlined in Figure 1A 
and is a combination of previously published protocols (Chambers 
et al., 2009; Yuan et al., 2011). Specifically, hESCs were seeded onto 
PA6 feeder cells, cultured 1 wk in the presence of SMAD inhibitor 
and noggin, and then cultured an additional 3 wk for neuronal pre-
cursor induction. Neural rosettes (Figure 1B) were selected, and 
cells were cultured another ∼4 wk with BDNF, GDNF, and cAMP for 
neuronal differentiation.
finding that the endocytic sorting pathway for the β-secretase is lim-
ited largely to the soma, where processing is postulated to occur 
(Sannerud et al., 2011).
Another model proposes local processing in axons/synapses, 
with extracellular APP fragments potentially secreted directly from 
the region in which they were processed. This model is supported 
by evidence for colocalization of processing enzymes together with 
APP in vesicles (Kamal et al., 2001) and evidence that synaptic activ-
ity in vivo increases endocytosis-dependent Aβ release into the 
brain (Cirrito et al., 2008; Tampellini et al., 2009; Das et al., 2013). 
The finding that Aβ secretion can depend on both synaptic activity 
and endocytosis implicates the synapse as a site of processing and 
secretion.
It is feasible that some combination of these two pathways oc-
curs in neurons; however, the subcellular sorting and processing of 
endogenous APP in neurons has not yet been directly examined. 
The location of Aβ and its accompanying toxicity, be it synaptic or 
diffuse, axonal or dendritic, is dependent on the location of secre-
tion and processing of APP in neurons. Additionally, shifts in the lo-
cation of Aβ secretion may be part of the disease process. Thus 
discovering the subcellular details of APP processing and secretion 
is important for insight into the AD process.
To understand typical APP sorting and processing, it is important 
to study pathways and processing in the context of endogenous 
levels of APP protein. This is because there is considerable evidence 
that overexpression of APP can alter the sorting and trafficking of 
APP in neurons (Cataldo et al., 2003; Muresan and Muresan, 2007). 
In fact, overexpression of APP can cause alterations in axonal trans-
port dynamics and change the content of axonal APP vesicles (Tor-
roja et al., 1999; Gunawardena and Goldstein, 2001; Stokin et al., 
2005; Muresan et al., 2009). Furthermore, a single extra copy of APP 
in the human genome will cause early-onset AD (Lai and Williams, 
1989; Sleegers et al., 2006). However, research on endogenous APP 
in neurons has been limited due to several technical constraints.
FIGURE 1: Human neuronal differentiation and microfluidic devices to fluidically isolate axons. (A) Schematic of 
differentiation steps. (B) Neural rosette (arrow) with neuronal projections (arrowhead) growing on PA6 feeder layers. 
(C) βIIItub (Tuj1) in green and nestin in red. (D) p-NFH axons in green and NeuN nuclei in red. (E) Synaptophysin in red and 
Tuj1 in green. (F) Tyrosine hydroxylase in red and Tuj1 in green. (G) GABA in red and p-NFH in green. Scale bars: 
(B–D and G) 100 μm; (E) 10 μm; (F) 20 μm. (H and I) p-NFH (in red) and Map2 (in green) immunofluorescence of human day 
36 neurons in microfluidic chambers. White lines denote fluidic barriers; S, soma; A, axons. (J) Diagram of new microfluidic 
chamber design. Neurons are plated in the two somal chambers (yellow), and one central axonal chamber is shown in red.
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Axons of neurons expressing endogenous APP secrete sAPP 
and Aβ
To directly measure the secretion of APP fragments from axons ver-
sus bulk somal culture (composed of soma/dendrites and axons), we 
cultured primary hippocampal neurons for 10 d in microfluidic 
chambers and then applied fresh media to both somal and axonal 
compartments. An additional volume of 50 μl in the axonal compart-
ment maintained fluidic isolation of the axons. After 24 h, condi-
tioned media were collected and Aβ amounts were measured by 
electro-chemiluminescent (ECL) immunoassay, which is sufficiently 
sensitive to detect endogenous APP fragments secreted from the 
∼2000 axons present in a chamber (see Materials and Methods). No 
assay was found to reliably detect mouse sAPPα at these concentra-
tions. The immunoassay used the 4G8 antibody to detect mouse 
Aβ, which could also, in theory, detect P3. Specificity of the 4G8 kit 
was tested with human conditioned media on both the 4G8 kit and 
a 6E10 human-specific kit, which does not detect P3. No difference 
in Aβ measurements was detected between the two kits, indicating 
that 4G8 measurements of Aβ are not significantly affected by P3 
levels.
Axons from mouse hippocampal cultures were found to secrete 
detectable amounts of Aβ40, whereas Aβ38, Aβ42, and sAPPβ were 
below detection limits in these experiments. The concentration of 
Aβ40 in the axonal compartment after 24 h of axonal secretion aver-
aged 17.1 ± 4.9 pM per chamber, while the bulk culture (whole neu-
rons) contained an average of 588 ± 364 pM of Aβ40 after 24 h of 
somatic secretion (n = 13; Figure 2A). The number of molecules se-
creted from an individual axon was determined by fixation of a 
subset of chambers and counting of p-NFH–positive axons (mean 
1030 ± 130 axons/chamber). Previous work measuring Aβ in brain 
slices or cultures with established synapses indicates a majority of 
Aβ is released through synaptic vesicle exocytosis and is therefore 
most likely secreted solely from axon terminals (Cirrito et al., 2008; 
Tampellini et al., 2009). As such, we treated each axon as a point 
source for Aβ secretion. Additionally, axonal staining compared with 
Aβ measurements showed concentrations of Aβ were independent 
of whether axons had just begun to enter the axon compartment or 
were fully extended. The Pearson’s correlation coefficient between 
Aβ40 concentrations and axon number is 0.78 for mouse and 0.87 
for human samples. We calculated the amount of secretion per axon 
by multiplying the sample volume (150 μl in the axonal compart-
ment and 125 μl in each somatic chamber) by the APP fragment 
concentration, divided by the number of axons per chamber. To es-
timate the number of molecules secreted, we multiplied the frag-
ment concentration by Avogadro’s number, which results in an esti-
mate of 4.0 × 105 ± 6 × 104 Aβ40 molecules secreted per axon over 
a 24-h period (Figure 2B). This may be an underestimate of total Aβ 
secretion, as some protein may be degraded over the 24-h sam-
pling period.
For calculation of the number of molecules secreted per soma, 
cell number was quantified by counting NeuN-positive nuclei 
(∼60,000 nuclei per chamber). As only ∼2% of the neurons in a cham-
ber are near enough to the microfluidic channels to project axons 
through, 98% of the cells in the somal compartment also have axons 
in that compartment. To account for the axonal contribution of Aβ to 
the somal measurements, we estimated the axonal number by sub-
tracting the number of axons in the axonal compartment from the 
number of cells in the somal compartment. This assumes that each 
cell has one axon and that axons in the axonal compartment secrete 
the same amount as axons in the somal compartment. The axonal 
contribution was calculated by multiplying the number of molecules 
per axon by the number of axons in the somal compartment and 
Following differentiation, cells expressed several postmitotic 
neuronal markers such as β- III tubulin (βIIItub; Figure 1C), the neu-
ronal nuclei marker NeuN (Figure 1D), polarity markers phospho-
neurofilament heavy chain (p-NFH; axonal; Figure 1, D and H) and 
Map2 a+b (dendritic; Figure 1I), as well as synaptic proteins such as 
synaptophysin (Figure 1E) and neurotransmitter markers such as TH 
(Figure 1F) and GABA (Figure 1G). Efficiency of neuronal induction 
varies between hESC lines, but the addition of SMAD inhibitors and 
noggin reduces this variation. The efficiency and neurotransmitter 
type are described in previously published reports for this PA6-
based induction method (Buytaert-Hoefen et al., 2004; Israel et al., 
2012). The successful and consistent differentiation of hESCs into 
neurons via stromal induction allowed for biochemical or other anal-
ysis of endogenous human neuronal proteins.
Fluidic separation of axons from neuronal cell bodies
Region-specific aggregation of Aβ and synaptic toxicity of APP frag-
ments raised the possibility that the regional processing and secre-
tion of APP within a neuron may be an important factor in the patho-
genesis of AD (Brunholz et al., 2012). To directly determine the 
subcellular location of processing and secretion of endogenous APP 
fragments from neurons, we developed a microfluidic culture sys-
tem to separate axons from bulk neuronal culture. Microfluidic cul-
ture systems can isolate pure axons without contamination from cell 
soma or dendrites (Taylor et al., 2005). The chamber design used in 
past publications did not provide enough cellular material to do 
biochemistry and were designed for dissociated cells.
Thus we developed a modified design that would both maxi-
mize the number of pure axons for biochemical analysis, as well as 
allow for culture of human rosettes during differentiation, which can 
be cell masses several millimeters in diameter. Our design entails 
two open “soma” compartments (3 mm × 23 mm × 10 mm) con-
nected by capillary channels to a single central “axonal” channel 
compartment (3 mm × 100 μm × 39 mm) (Figure 1J). The connecting 
capillary channels (10 μm × 3 μm × 450 μm) draw axons from human 
or mouse neurons to project through to the axon compartment but 
are sufficiently long to exclude dendrites. Fluidic isolation of com-
partments was established by adding a slightly higher medium 
volume in the axonal compartment, thus creating a slow flow into 
the somal compartment, which prevents diffusion of somal contami-
nants into axonal samples. This hydrostatic differential ensures that 
materials secreted from axons can be selectively and rigorously 
evaluated.
We discovered that there was a significant failure rate of fluidic 
isolation in these and other previously described types of compart-
ments due to leakage of chambers. Thus we found it essential to 
verify fluidic isolation in our experiments by routinely testing isola-
tion of the axonal compartment using a 4-kDa fluorescein isothio-
cyanate (FITC)-labeled dextran. FITC-dextran was not detectable in 
the axonal chamber after 24 h (Supplemental Figure S1A). In all sub-
sequent microfluidic chamber experiments, labeled dextran was al-
ways included in the somal media to detect and exclude the ∼5% of 
chambers that leak somal compartment components into axonal 
compartments.
Neurons differentiated from hESCs extended p-NFH–positive 
(Figure 1H and Supplemental Figure S1B) axons into the axonal 
chamber, while Map2-positive dendrites were excluded (Figure 1I). 
Primary neuronal cultures from wild-type mouse hippocampi also 
grew well in modified culture chambers and, after 10 d in vitro, 
sent robust, βIIItub-positive axonal projections through the chan-
nels, while Map2-positive dendrites were excluded (Supplemental 
Figure S1, C and D).
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per-soma measurements similar to the 
mouse measurements. However, for a sub-
set of chambers, per-axon measurements 
were obtained using the same calculations 
as used for the hippocampal neurons. 
These calculations revealed that 1.7 × 106 ± 
5.3 × 105 molecules of sAPPβ, 2.3 × 106 ± 
6.6 × 105 molecules of sAPPα, 1.7 × 106 ± 
3.0 × 105 molecules of Aβ40, and 2.6 × 105 
± 1.1 × 104 molecules of Aβ42 were se-
creted per axon over a 24-h period (n = 7; 
Figure 2D). Chambers containing human 
neurons averaged 1600 ± 110 axons each. 
Thus axonal secretion of Aβ40 was ∼4 times 
higher from human neurons than from 
mouse neurons, possibly due to neuronal 
type or species differences. Also worth not-
ing, the sAPPβ to Aβ ratio is 1:1, the ex-
pected ratio if γ cleavage is near complete 
on β-cleaved C-terminal fragments.
Most APP fragments secreted from 
axons are processed in the cell soma
Previous work has led to multiple models for 
the location and sorting of endogenous APP 
into axons. One potential model proposes 
that APP processing occurs mainly in the 
soma, while another model proposes that 
most APP is processed locally in the axon 
shafts and/or synapses. An additional, intermediate possibility is 
that neurons process APP both in the soma and the axon and can 
alter the location of processing depending on signaling, neuronal 
cell type, or other local conditions.
To distinguish among the possible models and to determine the 
location of APP processing in neurons, we again utilized microfluidic 
chambers. In addition to allowing for isolation of axons, the cham-
bers permit localized drug treatment of somal compartments. To 
determine the location of processing of APP in mouse and human 
cultured neurons, we applied inhibitors of the APP-processing pro-
teases (secretase inhibitors) to the cell soma while the axons were 
kept in isolation.
In hippocampal cultures, we found that inhibition of soma β- or 
γ-secretase activity caused a significant decrease in secretion of 
Aβ40 from the axons compared with vehicle-treated controls (Figure 
3A). Inhibition of β-secretase in the somal compartment by the in-
hibitor OM99-2 at 1 μM (β-inh) for 24 h reduced somal Aβ40 to 43 ± 
5% (one-way analysis of variance [ANOVA]: p < 0.0001; Tukey post 
hoc: p < 0.05; n = 6), with a trend toward reduction in axonal Aβ40 
to 64 ± 30% (n.s.; n = 6; Figure 3A). Inhibition of somal processing 
using 200 nM Compound E, a γ-secretase inhibitor, for 24 h reduced 
somal compartment Aβ40 secretion to 12% ± 2% of vehicle (Tukey 
post hoc: p < 0.0001; n = 12). Concurrent secretion of Aβ40 from 
axons was reduced to 30% ± 10% of vehicle (one-way ANOVA: 
p < 0.05; Tukey post hoc: p < 0.05; n = 12; Figure 3A). Finally, inhibi-
tion of both somal and axonal compartments resulted in a decrease 
of somatic Aβ40 to 9% ± 2% of vehicle (Tukey post hoc: p < 0.001; 
n = 5) and a concurrent decrease in axonal Aβ to 26% ± 9% of vehi-
cle. Secreted Aβ was normalized to the number of βIIItub-positive 
axons extending 40 μm into the axon compartment (to distinguish 
individual axons) and to the average number of nuclei for samples 
from the somal compartment. As the axonal Aβ was reduced only 
18 ± 10% less than the directly inhibited soma, we conclude that 
was subtracted from the somal compartment totals. Aβ amounts 
were then calculated as noted above. This calculation yields an esti-
mate of 7.3 × 105 ± 2 × 105 molecules of Aβ40 secreted per soma 
(Figure 2B).
From these measurements, we can thus calculate that an aver-
age of 37 ± 4% of total neuronal Aβ40 is secreted from the axons, 
per neuron, from mouse hippocampal neurons (calculated by divid-
ing the number of Aβ40 molecules secreted by axons to that se-
creted by the sum of Aβ40 secreted by axons and soma for each 
compartment). Our data provide the first direct, quantitative mea-
surement of endogenous Aβ secretion from any type of axon.
Human neurons differentiated from hESCs were cultured in 
compartments and also sampled for APP fragment secretion in 
analogous experiments. Axons were fluidically isolated, and media 
were collected 24 h later. Axons from human neurons secreted de-
tectable amounts of Aβ40, Aβ42, sAPPβ, and sAPPα. Axonal con-
ditioned media from human neurons contained 45 ± 10 pM Aβ40 
and 10 ± 3 pM Aβ42 in 200 μl media per chamber, and bulk (soma) 
culture conditioned media contained 600 ± 100 pM Aβ40 and 100 
± 30 pM Aβ42 in 200 μl of media over 24 h (n = 14; Figure 2B). This 
is approximately a 5:1 ratio of Aβ40:42 in the axonal compartment 
and 6:1 ratio in the somal compartments, which is similar to pub-
lished human brain samples (Lewczuk et al., 2004). Additionally, 
sAPPβ was measured in media at a concentration of 58 ± 10 pM in 
the axon and 680 ± 60 pM in the bulk (soma + axon) neuronal 
compartment, while sAPPα was measured at 210 ± 80 pM in the 
axon compartment and 3000 ± 630 pM in the somal compartment 
(n = 14; Figure 2C). Soluble APP fragments showed higher variabil-
ity than other measurements, possibly due to degradation or 
cleavage after secretion.
The neuronal rosettes used for differentiation of human neu-
rons produce large masses of neurons. Owing to these aggregates 
and the presence of nonneuronal cells, it was not possible to get 
FIGURE 2: Mouse and human neurons secrete APP fragments from axons. (A) Secreted Aβ40 
from mouse hippocampal neurons after 24 h. (B) Number of molecules of Aβ40 secreted per 
axon or cell body of mouse neurons in 24 h. (C) sAPPβ, sAPPα, and Aβ40 and Aβ42 measurements 
from human differentiated neurons after 24 h, in compartments 30–40 d. (D) Number of 
molecules of sAPPβ, sAPPα, and Aβ40 and Aβ42 secreted per axon of human neurons in 24 h. 
Error bars are SE.
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Aβ40 secretion was reduced in the soma by 200 nM Compound E 
to 32 ± 4% of vehicle (one-way ANOVA: p < 0.0001; Tukey post hoc 
p = 0.0001; n = 5), and in the axons to 68 ± 3% of vehicle (one-way 
ANOVA: p < 0.001; Tukey post hoc: p = 0.001; n = 4) (Figure 3B). 
Additionally, β inhibitor IV reduced somal Aβ to 37 ± 5% (p = 0.0001; 
n = 5) and axonal Aβ to 77 ± 7% (p = 0.008; n = 4). sAPPβ was re-
duced in soma to 41 ± 8% of vehicle (one-way ANOVA: p < 0.001; 
Tukey post hoc: p = 0.0002) by β inhibitor but not significantly 
changed by Compound E (decreased to 79 ± 6%; p = 0.07) (Figure 
3C). Axonal measurements of sAPPβ varied widely and thus showed 
no significant differences (one-way ANOVA: p = 0.41). These results 
could indicate sAPPβ itself is not transcytosed, or they may reflect 
the high variance in this experiment masking possible drug effects. 
In human neurons, 50–70% of Aβ secreted from axons was β cleaved 
in the soma, and 60–70% was γ cleaved in the soma. Direct inhibi-
tion of axonal processing is not possible, due to the flow of media 
from the axon compartment into the somal compartment during 
axonal isolation, leading to inhibition of both compartments.
It is interesting to note that, although human neurons show con-
sistent reduction of axonal Aβ secretion upon somatic inhibition of 
processing, this reduction is smaller in magnitude than in the mouse 
hippocampal cultures (60–70% in human vs. 70–90% in mouse hip-
pocampal neurons). The increase in local axonal processing may 
represent differences between species or neuron type and further 
underscores the importance of studies on human neurons.
To address the possibility that inhibitor applied in the somato-
dendritic compartment may be bound and actively transported into 
axons, effectively inhibiting processing locally in axons, we calcu-
lated the possible contribution of drugs applied to the soma that 
could affect axonal processing. With a maximum axon diameter of 
0.8 μm, an axon length of 1 mm, and an average of 1600 axons per 
chamber, the total axonal volume would be ∼8 × 10−4 mm3. With an 
axonal compartment volume of 200 μl of media, we calculated the 
volume of axons in the axonal chamber to be 1/250,000th the vol-
ume of media in the axonal chamber. The inhibitors are not prefer-
entially retained within the cell, so this dilution would lead all inhibi-
tors to diffuse away from the enzymes into the untreated axonal 
media. This dilution factor leads to a maximum possible drug con-
centration of 0.8 pM for Compound E, 4 pM for OM99-2, and 8 pM 
for β inhibitor IV, which is well below the inhibitory constants of the 
inhibitors (IC50 = 100 nM Compound E, IC50 = 70 nM OM99-2, IC50 
= 36 nM β inhibitor IV; Seiffert et al., 2000; Stachel et al., 2004; 
Garino et al., 2006). Therefore these estimates suggest that the 
effect on axonal secretion is not caused by local inhibition due to 
inhibitor transported from soma to axon.
Somatic processing of many axonal APP fragments requires 
endocytosis
If APP fragments are generated in the soma before transport into 
axons, it is important to determine the pathways of APP processing 
and sorting before axonal entry. One possibility is that processing of 
APP occurs in the Golgi/secretory pathway en route to sorting of 
secretory-derived vesicles into the axon. However, it has been re-
ported that BACE activity is enriched in late or recycling endosomes 
and that endocytosis is required for the production of a significant 
portion of the Aβ secreted from nonneuronal and neuronal cells 
(Koo and Squazzo, 1994; Kinoshita et al., 2003; Carey et al., 2005).
We tested whether APP fragments and/or the secretase machin-
ery are endocytosed from the somatodendritic cell membrane be-
fore being sorted into axons. This pathway has been suggested for 
various axonal proteins, including L1/NgCAM, TrkA, Caspr2, and 
CB1R (Wisco et al., 2003; Leterrier et al., 2006; Ascano et al., 2009; 
70–90% of γ processing occurred in the soma. The difference in 
axonal secretion between soma-only γ inhibition (to 30%) and total 
(somal and axonal) inhibition (26%) was only 4%, indicating that up 
to 96% of axonal Aβ produced in this time frame could be pro-
cessed in the soma. The lack of inhibition of axonal Aβ to levels seen 
in the somal samples, even with global application of inhibitor, may 
represent a pool of intracellular axonal Aβ that can be released over 
time, even during secretase inhibition. For β processing, axonal Aβ 
was 22 ± 30% less reduced than directly inhibited soma, so 40–100% 
of β processing occurred in the soma. The high variance of axonal 
Aβ resulted in the large range estimates. However, the general 
trends toward somatic processing and axonal secretion are striking, 
despite biological variance. Overall our measurements suggest that 
70–90% of Aβ secreted from axons was processed in the soma in 
hippocampal neurons in these conditions.
A similar result was also obtained in human differentiated neu-
rons. Neurons in compartments were treated with somal application 
of secretase inhibitors as in the mouse experiments. In human cells, 
FIGURE 3: Inhibition of secretase activity in soma reduces axonal 
secretion of Aβ. (A) Aβ40 from mouse hippocampal neurons in 
compartments, relative to vehicle control. Samples were treated with 
vehicle (DMSO), β inhibitor (OM99-2), or γ inhibitor (Compound E) in 
the somal compartment, or γ inhibitor on soma and axon (S&A) for 
24 h before collection. (B) Aβ40 from human neurons in compartments, 
treated with vehicle, γ inhibitor (Compound E), or β inhibitor IV for 
24 h in the somal compartment, relative to control. (C) sAPPβ from 
human neurons in compartments, treated with vehicle, γ inhibitor 
(Compound E), or β inhibitor IV on the soma for 24 h, relative to 
control. Error bars are SE; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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production. MCP1 sorting has not been as-
sociated with APP in normal neurons. As 
predicted, axonal MCP1 secretion was not 
reduced by endocytosis inhibition (Figure 
4C), indicating that the effect on axonal se-
cretion of Aβ40 is not due to a global dis-
ruption in axonal sorting or cell toxicity. 
Together these data indicated that endocy-
tosis in the soma is a major pathway for the 
generation of axonal Aβ.
FL-APP is not sorted into axons via 
transcytosis
The evidence that 70–90% of APP frag-
ments secreted from axons required so-
matic endocytosis before axonal entry led 
us to ask whether APP itself was sorted into 
the axon following endocytosis from the 
somatodendritic cell membrane. Previous 
literature has been contradictory regarding 
the pathway utilized by APP for delivery to 
axons (Koo et al., 1990; Simons et al., 1995; 
Cai et al., 2003).
To test whether FL-APP sorting into ax-
ons is endocytosis dependent, we used the 
endocytosis inhibitor dynasore on hip-
pocampal neurons. Cells were labeled with 
an N- or C-terminal antibody to APP and 
the dendritic marker Map2 (Figure 5A). If 
fragments were sorted separately from each other, discordance 
between the N- and C-terminal antibodies would be expected. 
The specificity of the antibodies was verified in APP−/− mice. The 
immunofluorescence intensity of the C-terminal antibody was dra-
matically diminished in APP−/− neurons, with most of the vesicles 
barely in the detectable range (Supplemental Figure S3A). Thus 
this antibody is suitable for overall neurite intensity measurements. 
The N-terminal antibody (labeled APP A8967) also had no de-
crease in vesicle number but showed a modest decrease in vesicle 
intensity, indicative of moderate nonspecific staining (Supplemen-
tal Figure S3C). The specificity of these antibodies was taken into 
account when interpreting experiments.
The distribution of staining in whole dendrites versus axons (D:A 
ratio) was quantified. For proteins previously demonstrated to travel 
to axons via transcytosis, inhibition of endocytosis greatly reduced 
the appearance of the protein in axons and increased in dendrites 
(represented by an increase in D:A ratio; Yap et al., 2008). In un-
treated neurons, APP levels were slightly higher in dendrites than in 
axons (N-terminal antibody D:A = 1.7 ± 0.1, C-terminal antibody 
D:A = 1.5 ± 0.1; Figure 5B). Although the N-terminal D:A ratio was 
slightly higher than with a C-terminal antibody, these ratios were 
not significantly different when tested by analysis of covariance 
(ANCOVA). Unlike proteins shown to be transcytosed, the D:A ratio 
of APP was unchanged after 24 h of dynasore treatment (N-terminal 
antibody D:A = 1.8 ± 0.07, C-terminal antibody D:A = 1.4 ± 0.05; 
Figure 5B). ANCOVA tests show the D:A ratios did not significantly 
change between conditions (change in slopes: N-terminal p = 0.13, 
C-terminal p = 0.86), and overall brightness values did not signifi-
cantly change (change in intercepts: N-terminal p = 0.65, C-terminal 
p = 0.64). In contrast, a 6-h cycloheximide treatment decreased ax-
onal APP staining 75%, and axonal intensity decreased 15% after 
1 h of cycloheximide treatment (unpublished data), establishing the 
sensitivity of our assay to changes as small as 15%.
Bel et al., 2009). This endocytosis and sorting pathway is termed 
“transcytosis” and is comparable with the sorting process from ba-
solateral to apical membranes that occurs in polarized epithelia 
(Figure 4A).
To test the hypothesis that axonal APP fragments are dependent 
on somatic endocytosis, we first evaluated whether Aβ secretion from 
axons was dependent on endocytosis in the cell body. To do this, we 
used the dynamin inhibitor dynasore (Macia et al., 2006). Dynasore 
effectively inhibited clathrin-mediated endocytosis in hippocampal 
neurons, as demonstrated by uptake of Alexa Fluor 568–transferrin, 
the internalization of which was robust in neurons and was 95% inhib-
ited by 100 μM dynasore after 4–6 h (unpublished data) and 60% in-
hibited after 24 h of treatment (Supplemental Figure S2, A and B). We 
applied dynasore to hippocampal neurons in chambers, such that dy-
nasore was applied to somal compartment medium while the axonal 
compartment was isolated. After 24 h, medium was collected and 
sampled for Aβ40. The Aβ40 secreted from hippocampal neurons in 
the somal compartment after dynasore treatment was reduced to 
43 ± 4% of vehicle (t test: p = 5 × 108) compared with vehicle-treated 
controls (Figure 4B), similar to previously published results of endo-
cytic inhibition (Carey et al., 2005). As can be seen in the transferrin 
uptake assay (Supplemental Figure S2B), inhibition by dynasore after 
24 h was incomplete, so some Aβ was still produced. Axonal Aβ40 
was also reduced to 61 ± 10% (p = 0.013) upon somal treatment with 
dynasore (Figure 4B). The difference between the reduction in the 
directly inhibited soma and uninhibited axons was 18 ± 10%. This sug-
gests that 70–90% of inhibitable axonal Aβ was dependent on endo-
cytosis in the soma, comparable with the percentages of axonal Aβ 
that were processed in the soma in the secretase experiments.
To confirm that transcytosis was not due to a global disruption 
of axonal sorting caused by endocytic inhibition, we also measured 
axonal and somal secretion of MCP1. MCP1 is a chemokine 
secreted from axons and should not depend on endocytosis for 
FIGURE 4: Inhibition of somatic endocytosis reduces axonally secreted Aβ. (A) Neuronal 
transcytosis. Yellow vesicles are proposed to travel by a direct, secretory pathway, while the 
green vesicles travel via an indirect, endosomal transcytosis pathway. (B) Somal compartments 
treated with vehicle (DMSO) or dynasore. Mouse Aβ40 from hippocampal neurons normalized 
to nuclei or axon number, relative to vehicle control. (C) Mouse MCP1 from same samples as in 
B, normalized to nuclei or axon number, relative to control. Error bars are SE; *, p < 0.05; 
***, p < 0.001.
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This hybrid secretory/endocytic route has 
been observed in polarized epithelia for 
cargo such as p75 and apical-variant VSVG 
(Weisz and Rodriguez-Boulan, 2009). If 
FL-APP indeed arrives in the axons through 
multiple delivery pathways, APP vesicles 
would belong to various vesicle populations.
For determining the identity of axonal 
APP vesicles, differentiated human neurons 
were fixed and labeled by immunofluores-
cence for both APP and endosomal markers 
(Figure 6). High-resolution images of axons 
were acquired and analyzed using a Matlab 
software package described previously 
(Szpankowski et al., 2012). This meticulously 
validated software uses a detection algo-
rithm to determine subpixel locations of 
puncta by fitting Gaussian functions to the 
fluorescence data and is particularly well 
suited to rigorous and quantitative colocal-
ization analysis when analyzing images 
densely populated with punctate vesicular 
staining.
The APP puncta (vesicles) were colocal-
ized with Rab11 (recycling endosome; 
Figure 6A), Rab5 (early endosome; Figure 
6B), or Rab7 (late endosome; Figure 6C) 
vesicles and BACE (Figure 6D). APP colocal-
ization with endosome markers or BACE 
was not dependent on location within the 
axon, as shown in Figure 6, E and F.
Next we determined whether APP puncta populations in the 
axon changed after dynasore treatment. The effects of dynasore on 
APP in human neurons were confirmed, with an increase in anti-
body-labeled surface APP after dynasore treatment (Figure 7A); re-
duced levels of Aβ38, 40, and 42; and a slight increase in the 
sAPPα/β ratio (Supplemental Figure S5, A and B). APP undergoes α 
cleavage on the cell surface, so some of the FL-APP expected to 
accumulate at the surface is instead secreted as sAPPα.
APP puncta were labeled with two N-terminal or C-terminal anti-
bodies to elucidate any possible sorting discrepancies between FL-
APP or N- and C-terminal fragments and to control for antibody 
ambiguity. The Epitomics and APP “Jonas” C-terminal antibodies 
were used for C-terminal staining, as the Epitomics antibody has 
been previously characterized (Guo et al., 2012), and the Jonas an-
tibody showed both a decrease in vesicle intensity and number in 
APP knockout neurons (Supplemental Figure S3B). N-terminal anti-
bodies were 5a3/1g7 (Koo and Squazzo, 1994) and a less-specific 
sigma N-terminal antibody A8967, characterized in Supplemental 
Figure S3C. All APP-positive puncta were detected and counted, 
and then double-labeled puncta were detected and measured as a 
percentage of total APP vesicles. Puncta density, percent colocaliza-
tion, and staining intensity (vesicle loading) were measured in axons 
of vehicle- and dynasore-treated neurons.
Measurements of puncta density were calculated as puncta de-
tected per micrometer. A slight but significant reduction in APP C-
terminal puncta density was observed after 18 h of endocytic inhibi-
tion (APP Epitomics: 89 ± 3%, p = 0.003, vehicle n = 43 axons, 
dynasore n = 39 axons; APP Jonas: 92 ± 2%, p = 0.0004, vehicle 
n = 37, dynasore n = 44; Figure 7B). A slight increase in N-terminal 
vesicle density was observed with APP N-terminal antibody A8967 
(108 ± 4%, p = 0.03) but was not confirmed with antibody 5a3/1g7. 
Axonal APP fluorescence and D:A ratio were unchanged with 
either N- or C-terminal antibody, leading us to conclude that APP 
can enter the axons in an endocytosis-independent pathway, either 
during normal axonal sorting or specifically during endocytosis 
inhibition.
To address the possibility that axonal APP immunofluorescence 
is not affected by dynasore treatment due to a stabilized pool of 
APP that remained in the axons during the duration of dynasore 
treatment, or due to nonspecific binding of antibodies, we under-
took another approach to test for transcytosis of FL-APP. In this as-
say, we measured FL-APP–yellow fluorescent protein (YFP) particle 
movement in axons proximal to the cell body (Supplemental Figure 
S4A). Neurons were pretreated for 4 h with dynasore and then im-
aged live to measure movement of APP-YFP vesicles. The number 
of anterograde-moving particles entering the axon from the cell 
bodies was not decreased by dynasore treatment (vehicle = 274 
vesicles, dynasore = 218 vesicles; Supplemental Figure S4B). This 
confirms the observation that APP can enter the axon during endo-
cytic inhibition.
Endosome-derived populations of APP vesicles in axons
Our results indicate that APP fragments undergo a complex sorting 
process before axonal entry. Multiple mechanisms can explain this 
phenomenon. One scenario includes FL-APP traveling through mul-
tiple pathways, both directly to the axon through the secretory path-
way in an unprocessed form, as well as through transcytosis, where it 
would encounter the secretase machinery and be processed, and 
some or all fragments transported into axons. Another possibility is 
that FL-APP that is targeted to axons does not travel to the somatic 
cell surface but rather intersects in the soma with an intermediate, 
endosome-associated vesicle containing the processing machinery. 
FIGURE 5: APP does not require somatic endocytosis for axonal delivery. (A) Immuno-
cytochemistry of mouse hippocampal neuron. Green is Map2, labeling dendrites. Red is a 
C-terminal APP antibody. Blue arrow denotes a Map2-negative axon. Scale bar: 50 μm. 
(B) Quantification of neurons labeled as in A. APP N-terminal– (A8967) and C-terminal– 
(Chemicon) specific antibody-labeled neurons treated with vehicle or dynasore for 24 h. 
Dendrite to axonal fluorescence ratio is calculated. Error bars are SE.
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of the axonal APP vesicles are still sorted into axons regardless of 
endocytic inhibition.
Next we calculated colocalization of APP, BACE, and endocytic 
markers in the human neurons. For antibody compatibility, one C- or 
N-terminal antibody was used with each vesicle marker. We found 
that, in the axons of human neurons, 48 ± 1.6% of APP-containing 
vesicles colocalized with BACE (Figure 7D), but colocalization did 
not change with dynasore treatment. This is higher than that re-
ported in dendrites with exogenous labeled APP and BACE (Das 
et al., 2013). Of all the vesicle types, the only significant change was 
a moderate decrease in the number of Rab11 particles colocalized 
with C-terminal APP (Figure 7E, from 42 ± 1.5% to 29 ± 0.73%, 
p < 0.0001, vehicle n = 19 axons, dynasore n = 22 axons). It is inter-
esting that the only vesicle class affected was recycling endosomes, 
which have been shown to be necessary for APP processing. Also 
notable is the fact that ∼75% of axonal APP vesicles in vehicle-
treated conditions are positive for an endosomal marker.
Finally, the loading of protein into vesicles was measured by fluo-
rescence intensity per puncta. In APP vesicles, several antibodies 
had statistically significant differences in staining intensity, but none 
were confirmed by a second antibody (Figure 7F). This may be due 
to the very large sample size and the flaws in specificity for each 
antibody (APP Jonas: 82 ± 2%, Mann-Whitney U-test p < 0.001, ve-
hicle n = 3238 puncta, dynasore n = 2467 puncta; N-terminal A8967: 
124 ± 3%, p < 0.001, vehicle n = 2791, dynasore n = 2849; N-termi-
nal 5a3: 84±2%, p < 0.001, vehicle n = 1908, dynasore n = 1685).
A consistent change was observed in the amount of Rab11 and 
BACE loading in APP vesicles (Figure 7G). Rab11 levels increased in 
both C- and N-terminal–labeled APP vesicles (137 ± 6%, Mann-
Whitney U-test: p < 0.001, vehicle n = 398 puncta, dynasore n = 
299), while BACE levels were decreased in both C- and N-terminal–
labeled APP vesicles (to 88 ± 2%, p < 0.001, vehicle n = 349, dynas-
ore n = 297 and 85 ± 3%, p < 0.001, vehicle n vehicle n = 381, dyna-
sore n = 346, respectively). Although the magnitude of the changes 
in loading on vesicles is not large, these population shifts are consis-
tent with neuronal dependence on endocytosis for processed frag-
ments, but most APP and BACE proteins enter the axon indepen-
dent of endocytosis.
DISCUSSION
In this study, we have made three principal findings. First, we 
found that both mouse and human neurons secrete detectable 
amounts of APP fragments from axons and that axons contribute 
∼40% of the total secreted neuronal Aβ. Second, we demon-
strated that a large fraction, ∼80%, of the Aβ secreted from axons 
was processed in the cell soma in a secretase- and endocytosis-
dependent pathway. Third, we identified multiple pathways for 
axonal sorting of APP, Aβ, and BACE, including both endosome-
dependent and endosome-independent sorting. These pathways 
lead to packaging of most APP and its fragments into axonal ves-
icles that have endosomal markers, and a subpopulation that 
includes BACE, indicating that most axonal APP passes through 
an endosomal compartment before axonal entry and thus is pri-
marily endosome derived. Together these findings indicate that 
the processing, sorting, and trafficking of APP and its fragments 
to axons are highly regulated in neurons and encompass multiple 
pathways.
Previous studies have focused on the role of APP processing 
in the pathology of AD. Much of this work, however, has been 
performed in nonneuronal cells or in neurons overexpressing 
APP. Biochemical and cellular evidence to date have implicated: 
1) a major role for synaptic activity and endocytosis in Aβ 
Rab5 and Rab11 vesicle densities were unchanged, only Rab7 
particles were diminished (p = 0.007; Figure 7C).The reduction of 
axonal C-terminal APP vesicles by only 10 ± 3% indicates that most 
FIGURE 6: Axonal APP vesicles colocalize with endosome markers. 
Immunocytochemistry of axons with (A) Rab11 and C-terminal APP 
Epitomics (APPE), (B) Rab5 and N-terminal A8967 (APPN), (C) Rab7 
and C-terminal APP Jonas (APPJ), and (D) BACE and N-terminal APP 
5a3/1g7 (APP5). Arrows indicate single-labeled APP vesicles. 
Arrowheads indicate double-labeled vesicles. Respective merged 
images are also shown. Scale bar: 5 μm. (E and F) Histogram plots of 
colocalization of two representative antibody pairs. Frequency of 
single-labeled puncta versus double-labeled puncta is plotted as a 
function of distribution along axon lengths.
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Our studies of neurons using microfluidic chambers enabled us 
to directly measure the amounts of endogenous levels of secreted 
APP fragments without overexpression of any pathway components. 
By using this system, we discovered in mouse and human axons that 
production, 2) distal axons as one possible source of amyloid 
deposits, and 3) a link between axonal transport function and 
disease (Kamal et al., 2000; Lazarov et al., 2002; Abramov et al., 
2009; Das et al., 2013).
FIGURE 7: Axonal APP vesicle profiles are largely unchanged after endocytic inhibition. (A–G) Veh = DMSO; 
Dyn = dynasore. (A) Anti-APP antibody surface labeling intensity per cell, normalized to Whole Cell Blue labeling, 
in differentiated human neurons. Cells treated with DMSO or dynasore 18 h. (B) APP vesicle density per micrometer 
in human neurons after 18 h of endocytic inhibition. APPE = C-terminal Epitomics; APPJ = C-terminal Jonas; 
APP5 = N-terminal APP 5a3/1g7; APPN = N-terminal APP Sigma-Aldrich 8967. (C) Endosomal and BACE vesicle density. 
(D) Percentage of APP vesicles that colocalize with endosomal markers or BACE. (E) Percentage of endosome or BACE 
vesicles that also contain APP. (F) APP vesicle-staining intensity. (G) Endosomal marker or BACE intensity on APP 
vesicles. Error bars are SE; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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contributing to disease (Van Den Heuvel et al., 2007), which could 
be attributed to a neuronal stress response involving the location of 
processing or secretion. The second question stems from the obser-
vation that FAD mutations may also affect APP processing and sort-
ing; previous work has shown that PS1 might normally regulate the 
exit of APP from the Golgi network, and FAD mutations in PS1 delay 
APP arrival at the cell surface. In addition to the early-onset familial 
mutations with a clear etiology, AD risk variants, such as those found 
in the SorLA or ApoE genes, are also connected to sorting of APP 
(Rogaeva et al., 2007; Marzolo and Bu, 2009). SorLA influences the 
sorting of APP from late endosomes into recycling endosomes 
(Andersen et al., 2005), suggesting that polymorphisms could 
change the subcellular sorting of APP and have subsequent down-
stream localization effects. These AD risk variants lend further cre-
dence to the importance of location of APP processing and Aβ se-
cretion in AD. Our findings highlight the importance of determining 
whether risk variants affect the localization of processing, particu-
larly in different neuronal compartments.
In summary, if the balance of somal versus axonal sorting and 
secretion is shifted in AD, it might be possible to screen for thera-
peutic agents that modulate this balance and shift the amyloid load 
away from axons and amyloid-sensitive synapses. Although there is 
still much to be learned about the pathological role of APP and Aβ, 
as well as other facets of AD, the development of more representa-
tive models, that include human neurons along with novel measure-
ments of the cellular location of APP processing and Aβ secretion, 
represent important steps to overcoming this disease.
MATERIALS AND METHODS
cDNA constructs
Human APP- YFP in pcDNA3 was a gift from Christoph Kaether. 
mCherry pcDNA3 was a gift from Roger Tsien (University of California, 
San Diego).
Antibodies and cell lines
Primary antibodies and dilutions used: anti–N-terminal APP A8967 
(1:100), GABA A2052 (1:1000), and human Map2a+b (1:1000) 
(Sigma-Aldrich, St. Louis, MO); N-terminal APP 5a3/1g7 (1:100) cour-
tesy of Eddie Koo (Koo et al., 1996); BACE 3D5 (1:200) courtesy of 
Robert Vassar (Zhao et al., 2007); C-terminal APP Jonas clone (1:100), 
C-terminal APP AB5352 (1:100), NeuN (1:100), and Synaptophysin 
(1:100) (Chemicon/Millipore, Darmstadt, Germany); C-terminal APP 
Y188 (1:100) (Epitomics, Cambridge, UK); p-NFH SMI31 (1:2000) and 
βIIItub-Tuj1 rabbit and mouse monoclonal (1:2000) (Covance, 
Princeton, NJ); chicken anti-Map2 (1:1000) (Abcam, Cambridge, 
UK); Nestin (1:300) (Millipore, Billerica, MA); Rab5 (1:100) and Rab7 
(1:100) (Santa Cruz, Dallas, TX); and Rab11 (1:100) (Becton Dickinson, 
Franklin Lakes, NJ). The cell lines used for differentiation of human 
neurons were PA6 stromal cells (Kawasaki et al., 2000), and the hESC 
lines HUES9 (Harvard Stem Cell) and HSF6 (University of California, 
San Francisco). HUES9 were cultured on an irradiated mouse embry-
onic fibroblast (MEF) layer in HUES medium containing Knockout-
DMEM (Life Technologies/Invitrogen, Carlsbad, CA), knockout serum 
replacement, nonessential amino acids, GlutaMAX, penicillin/strep-
tomycin (pen/strep) and β-mercaptoethanol (Invitrogen), and 
10 ng/ml bFGF (R&D Systems, Minneapolis, MN). HSF6 were grown 
on MEF feeder layers, in similar media, with the exception of Hi-glu-
cose DMEM instead of Knockout-DMEM and without plasmanate.
Differentiation of hESCs into neurons
HUES9 or HSF6 ES cells were plated on 80% confluent PA6 feeder 
cells at a density of 125 cells/cm2 in PA6 differentiation media 
70–90% and 60–70%, respectively, of Aβ fragments were processed 
in the cell body before delivery to the axon. We also found that Aβ 
fragments, but not necessarily APP itself, depended upon endocy-
tosis in the cell soma before being transported to axons. This re-
quirement for “transcytosis” or some other endocytosis-dependent 
pathway before processing and fragment entry into axons repre-
sents a previously unknown requirement for APP fragment sorting 
and delivery into axons.
On the basis of our results, we can propose two models for APP 
sorting and processing that include a dependence on somatic endo-
cytosis and processing. The first model is that APP itself goes to the 
axon through multiple distinct pathways. In this model, APP is sorted 
into axons via secretory vesicles, some of which merge before axonal 
entry with endosomes containing secretase complexes, and then 
APP and its fragments are sorted into axons in endosome-derived 
vesicles. Under this scenario, inhibition of endocytosis would prevent 
processing and would decrease the fragments bound for the axon, 
but direct-sorted APP would continue to arrive in the axon unpro-
cessed, perhaps along with additional compensatory APP to main-
tain a consistent steady-state concentration. The sorting of APP into 
the axon despite endocytic inhibition is consistent with work in non-
neuronal cells that found that C99–green fluorescent protein was 
sorted normally when dynamin is blocked (Kaether et al., 2006).
A second model posits that APP and BACE are both endocy-
tosed in the cell body, and at some point along the journey to the 
axon, the two vesicle types (clathrin dependent and independent) 
merge. In this case, perhaps APP and its processing machinery 
would continue to arrive in the axon while endocytosis is blocked, 
but without functional secretase activity, possibly due to disrupted 
timing or acidification. It is unlikely that altered BACE delivery into 
the axons alone causes the changes in axonal Aβ. This is supported 
by our finding that BACE levels in the axons decrease only slightly 
after endocytic inhibition and somatic inhibition of γ-secretase 
affects axonal Aβ, independent of β processing. These possibilities 
add an intriguing layer to the already complex regulation of APP 
processing and sorting in neurons.
Our finding that most axonally secreted Aβ comes from APP pro-
cessed in the cell soma is surprising. Although one study theorized 
that APP must be processed in the cell soma before being sorted 
into axons, a majority of the prior evidence supports a model by 
which most APP is processed and secreted locally from axons (Kamal 
et al., 2001; Cirrito et al., 2008; Muresan et al., 2009; Nikolaev et al., 
2009). It is important to note that these prior studies and our current 
results are not necessarily contradictory. One contributing factor to 
the apparent discrepancy is that these studies were performed in 
different neuronal types under different conditions. For example, it 
is plausible that neurons normally process most APP in the cell soma, 
but under stress, such as growth factor withdrawal, or in response to 
synaptic activity in mature synaptic circuits, local processing is acti-
vated (Nikolaev et al., 2009; Das et al., 2013). The axonal colocaliza-
tion experiments in our current study show β-secretase present in 
axons, a majority of which is in the same vesicles as APP. An addi-
tional intriguing possibility is that localization of APP processing is in 
a dynamic equilibrium that responds to normal functions. Further 
investigation is needed to understand the circumstances regulating 
APP processing in axons versus soma and dendrites.
The complexity of APP processing engenders two interesting 
questions: 1) Is the location of processing in neurons shifted in re-
sponse to damage or insult? 2) Do familial AD (FAD) mutations alter 
the location of processing and/or secretion? The first of these is of 
interest, because traumatic brain injury is a risk factor for AD, and 
previous work has focused on the damage responses of the brain 
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(MesoScale Discovery, Rockville, MD). For inhibitor experiments, 
200 nM Compound E, 1 μM OM99-2, or 2 μM β-secretase inhibitor 
IV (all from EMD) was added to media for 24 h before collection. 
For normalization, compartments were fixed after media collection 
and labeled with βIIItub (mouse) or p-NFH (human) and DAPI. In 
the axonal chamber, the total number of βIIItub-positive projec-
tions were counted and used for normalization of secreted pro-
teins. In the somal chamber, the average number of nuclei per 
frame were counted, and the average was used for normalization. 
In chambers containing human neurons, neuronal precursor cells 
occasionally can travel into the axonal compartment. When this 
occurred, these cells were counted, and their calculated contribu-
tion to axonal secreted proteins was subtracted, although their 
contribution was negligible.
Endocytosis dependence assays
Primary neurons were incubated with 100 μM dynasore (Tocris) for 
24 h before fixation and immunocytochemistry for N- or C-terminal 
APP and Map2. For determining the efficacy of dynamin inhibition, 
100 μg/ml Alexa Fluor 568–transferrin was added after drug treat-
ment and incubated at 37°C for 30 min. For surface APP quantifica-
tion, human neurons were incubated with vehicle or dynasore plus 
22C11 antibody for 18 h. Cells were fixed but not permeabilized 
and then labeled with anti-mouse Alexa Fluor 488 as well as Whole 
Cell Blue Stain (Pierce/Thermo). Samples were imaged on a Zeiss 
510 confocal microscope. For calculation of D:A ratio, Map2-posi-
tive or p-NFH–positive neurites were traced and measured using 
the NeuronJ plug-in for ImageJ (Meijering et al., 2004).
APP-YFP live imaging
Hippocampal neurons on coverslips were cotransfected with APP-
YFP and mCherry for 4 h using JetPrime (Polyplus-Transfection, 
Illkirch-Graffenstaden, France) and imaged 18 h after transfection. 
For dynasore drug treatment, medium containing 100 μM dynasore 
or dimethyl sulfoxide (DMSO) was added 4–6 h before imaging. 
Coverslips were imaged in a 37°C incubator with added CO2. For 
ensuring axon identification in neurons treated with dynasore, axons 
were determined by morphology using mCherry fluorescence, and 
APP-YFP movement was imaged by stream acquisition at 100× 
magnification with 100-ms exposure for 15 s on a Nikon epifluores-
cence microscope with a CoolSnap camera. Cultures were main-
tained at 37°C and 5% CO2 during imaging. Kymographs were ana-
lyzed in MetaMorph software.
Colocalization of endosome and APP markers
Hippocampal cultures were labeled by immunocytochemistry as de-
scribed above and imaged on a Deltavision RT deconvolution mi-
croscope. Individual slices (without deconvolution) were processed 
for colocalization in Matlab using a package developed in our lab, 
described and extensively validated previously using a 300-nm cut-
off for colocalization (Szpankowski et al., 2012). For intensity mea-
surements, the top and bottom 5% of vehicle-treated values were 
used as thresholds for all analyses.
Statistical analysis
Error bars in all charts represent SEM. Significance was calculated 
by one-way ANOVA followed by Tukey post hoc testing. Mouse 
Aβ values failed Levene’s test for homoscedasticity and the 
Kolmogorov–Smirnov test for normality, so were log-transformed 
before ANOVA and back-transformed for reporting. For D:A 
ratios, significance was tested by ANCOVA (http://vassarstats 
.net/vsancova.html). Immunofluorescence measurements were 
composed of Glasgow DMEM, Knockout Serum Replacement (KSR), 
sodium pyruvate, GlutaMAX, pen/strep, and BME (all Invitrogen). 
For the first 6 d of culture, 500 ng/ml noggin (R&D Systems) and 
10 μM SB431542 (Tocris, Bristol, UK) were added to PA6 differentia-
tion media. After ∼4 wk on PA6 cells, neural rosettes were hand se-
lected and plated onto coverslips coated with poly-l-ornithine and 
laminin and cultured in Neuronal Media (ScienCell Research Labs, 
Carlsbad, CA) for 4–6 d. To induce neuronal differentiation, we trans-
ferred cultures into media containing DMEM:F12 + GlutaMAX, B27, 
N2, pen/strep (all from Invitrogen), 20 ng/ml BDNF, 20 ng/ml GDNF 
(Preprotech, Rocky Hill, NJ), and 0.5 mM db-cAMP (Sigma-Aldrich) 
for 4–5 wk. For imaging experiments, differentiated neurons were 
fluorescence-activated cell sorted for neurons, as described previ-
ously (Yuan et al., 2011), and grown in glial-conditioned media. For 
immunocytochemistry of neuronal markers, cells on coverslips were 
fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) 
and blocked in 3% bovine serum albumin in PBS + 0.1% Triton-
X-100. Primary antibodies were diluted in blocking buffer and incu-
bated overnight. Alexa Fluor anti-rabbit, mouse (Invitrogen), and 
DyLight anti-chicken (Abcam) antibodies were incubated in blocking 
buffer for 1 h. Coverslips were mounted in ProLong Gold + 4′,6-di-
amidino-2-phenylindole (DAPI; Invitrogen).
Hippocampal neuron cultures
Hippocampal neurons were dissected from P0-P1 C57/BL6 or APP+/− 
or APP−/− (Apptm1Dbo/J) pups as previously described (Falzone et al., 
2009). Briefly, hippocampal brain sections were dissociated in 
papain and cultured in media containing Neurobasal-A, B27, and 
GlutaMAX on poly-l-lysine coated coverslips for 10 d before 
experimentation.
Compartmentalized microfluidic devices
Master molds were fabricated by photolithography, as previously 
described (Minteer, 2006), at the University of California, San Diego, 
Nano3 Cleanroom Facility. Devices were molded by soft lithography 
using Sylgard 182 (Ellsworth Adhesives, Germantown, WI) as previ-
ously described (Taylor et al., 2005). Cured, cut devices were washed 
sequentially in isopropanol, water, and 70% ethanol, and then dried 
and mounted onto glass coverslips. For human neurons, compart-
ments were plasma treated before mounting. Coverslips were 
coated with poly-l-lysine for hippocampal cultures or poly-l-orni-
thine/laminin for human neurons. For immunocytochemistry, neu-
rons were fixed with 4% PFA + 4% sucrose, and subsequent staining 
steps were carried out within the chambers. For confirmation of flu-
idic isolation, 50 μg/ml 4-kDa FITC-dextran (Invitrogen) was added 
to cultures. Testing routinely was straightforward and relied on dex-
tran introduction into both somal compartments, but not the axonal 
compartment, with the axonal compartment in isolation. After 24 h, 
samples from both somal and axonal compartments were collected 
and measured for dextran fluorescence.
Location of processing of APP and measurements 
of secretion
Neurons in compartments were transferred into fresh media, con-
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